These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 31236814)

  • 1. Non-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria to a large routine cohort.
    Riedel F; Heil J; Feißt M; Rezai M; Moderow M; Sohn C; Schütz F; Golatta M; Hennigs A
    Breast Cancer Res Treat; 2019 Sep; 177(2):457-467. PubMed ID: 31236814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analyzing non-sentinel axillary metastases in patients with T3-T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy.
    Riedel F; Heil J; Feisst M; Moderow M; von Au A; Domschke C; Michel L; Schaefgen B; Golatta M; Hennigs A
    Breast Cancer Res Treat; 2020 Nov; 184(2):627-636. PubMed ID: 32816190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
    Hennigs A; Köpke M; Feißt M; Riedel F; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Schneeweiss A; Heil J
    Breast Cancer Res Treat; 2019 Jan; 173(2):429-438. PubMed ID: 30315437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohort.
    Costaz H; Boulle D; Bertaut A; Rouffiac M; Beltjens F; Desmoulins I; Peignaux K; Ladoire S; Causeret S; Loustalot C; Padeano MM; Vincent L; Jankowski C; Arnould L; Coutant C
    Bull Cancer; 2022 Mar; 109(3):268-279. PubMed ID: 34838310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of the Use of Completion Axillary Lymph Node Dissection in Patients with T1/2N0M0 Breast Cancer and Tumour-Involved Sentinel Lymph Nodes Undergoing Mastectomy: A Cohort Study.
    Hennigs A; Riedel F; Feißt M; Köpke M; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Heil J
    Ann Surg Oncol; 2019 Aug; 26(8):2435-2443. PubMed ID: 31049766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends on Axillary Surgery in Nondistant Metastatic Breast Cancer Patients Treated Between 2011 and 2015: A Dutch Population-based Study in the ACOSOG-Z0011 and AMAROS Era.
    Poodt IGM; Spronk PER; Vugts G; van Dalen T; Peeters MTFDV; Rots ML; Kuijer A; Nieuwenhuijzen GAP; Schipper RJ
    Ann Surg; 2018 Dec; 268(6):1084-1090. PubMed ID: 28742702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
    Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
    JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort.
    Jung J; Han W; Lee ES; Jung SY; Han JH; Noh DY; Kim Y; Choi HJ; Lee JE; Nam SJ; Lee JW; Kim HJ; Um E; Kim JH; Park S; Cho YU
    Breast Cancer Res Treat; 2019 May; 175(1):203-215. PubMed ID: 30715659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of frozen section in sentinel lymph node biopsy for breast cancer in the era of the ACOSOG Z0011 and IBCSG 23-10 trials.
    Lombardi A; Nigri G; Maggi S; Stanzani G; Vitale V; Vecchione A; Nania A; Amanti C
    Surgeon; 2018 Aug; 16(4):232-236. PubMed ID: 29329752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Population-Based Study of the Effects of a Regional Guideline for Completion Axillary Lymph Node Dissection on Axillary Surgery in Patients with Breast Cancer.
    Tsao MW; Cornacchi SD; Hodgson N; Simunovic M; Thabane L; Cheng J; O'Brien MA; Strang B; Mukherjee SD; Lovrics PJ
    Ann Surg Oncol; 2016 Oct; 23(10):3354-64. PubMed ID: 27342830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The exportability of the ACOSOG Z0011 criteria for omitting axillary lymph node dissection after positive sentinel lymph node biopsy findings: a multicenter study.
    Delpech Y; Bricou A; Lousquy R; Hudry D; Jankowski C; Willecocq C; Thoury A; Loustalot C; Coutant C; Barranger E
    Ann Surg Oncol; 2013 Aug; 20(8):2556-61. PubMed ID: 23456432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgeon Bias in the Management of Positive Sentinel Lymph Nodes.
    Mathias BJ; Sun J; Sun W; Zhou JM; Fulp WJ; Laronga C; Lee MC; Kiluk JV
    Clin Breast Cancer; 2021 Feb; 21(1):74-79. PubMed ID: 32917535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential Impact of the Z0011 Trial on the Omission of Axillary Dissection: A Retrospective Cohort Study.
    Shinzato JY; Serra KP; Eugeni C; Cabello C; Cardoso-Filho C; Zeferino LC
    Rev Bras Ginecol Obstet; 2021 Apr; 43(4):297-303. PubMed ID: 33784760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors of non-sentinel lymph node metastasis in breast cancer with 1-2 sentinel lymph node macrometastases underwent total mastectomy: a case-control study.
    Huang Z; Wu Z; Zou QQ; Xie YJ; Li LH; Huang YP; Wu FM; Huang D; Pan YH; Yang JR
    World J Surg Oncol; 2023 Apr; 21(1):125. PubMed ID: 37024930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
    Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
    Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is SLN Biopsy Alone Safe in SLN Positive Breast Cancer Patients?
    van la Parra RF; de Wilt JH; Mol SJ; Mulder AH; de Roos WK; Bosscha K
    Breast J; 2015; 21(6):621-6. PubMed ID: 26391102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in Z0011-Eligible Patients.
    Barrio AV; Downs-Canner S; Edelweiss M; Van Zee KJ; Cody HS; Gemignani ML; Pilewskie ML; Plitas G; El-Tamer M; Kirstein L; Capko D; Patil S; Morrow M
    Ann Surg Oncol; 2020 May; 27(5):1617-1624. PubMed ID: 31820212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When is a completion axillary lymph node dissection necessary in the presence of a positive sentinel lymph node?
    Suyoi A; Bains SK; Kothari A; Douek M; Agbaje O; Hamed H; Fentiman I; Pinder S; Purushotham AD
    Eur J Cancer; 2014 Mar; 50(4):690-7. PubMed ID: 24331957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contemporary Axillary Management in cT1-2N0 Breast Cancer with One or Two Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database.
    Stafford AP; Hoskin TL; Day CN; Sanders SB; Boughey JC
    Ann Surg Oncol; 2022 Aug; 29(8):4740-4749. PubMed ID: 35451727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative axillary ultrasound in breast cancer: safely avoiding frozen section of sentinel lymph nodes in breast-conserving surgery.
    Ibrahim-Zada I; Grant CS; Glazebrook KN; Boughey JC
    J Am Coll Surg; 2013 Jul; 217(1):7-15; discussion 15-6. PubMed ID: 23628226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.